Synergistic effects of combined CTLA-4 and CD73 as well as combinations of PD-1 and CD73 blockade immunotherapies in breast cancer and colon carcinoma pre-clinical models (84, 85) have been observed. This evidence concerns the gene NT5E and colon carcinoma.